Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer
CTS effectively suppresses CRC progression. Its efficacy is associated with the coordinated modulation of the tumor-immune-microbiome axis, involving direct cytotoxicity, reduced PD-1+ T cell levels, and restructuring of the gut microbial community. These results highlight CTS as a promising multi-faceted therapeutic candidate and provide a preclinical rationale for its further development.
Authors
- Shiqi Feng (ORCID: https://orcid.org/0009-0001-6977-5168)
- Ruirong Tan (ORCID: https://orcid.org/0000-0003-1719-1416)
- Qiqian Wang (ORCID: https://orcid.org/0000-0001-7863-9734)
- Mengting Zhou (ORCID: https://orcid.org/0000-0002-2707-4902)
- Fenglin Luo
- Yu Jun Tan (ORCID: https://orcid.org/0000-0002-3828-9490)
- Zeneng Cheng (ORCID: https://orcid.org/0000-0001-9352-9744)
- Rui Li (ORCID: https://orcid.org/0000-0003-0056-7210)
- Zhenya Yang
Institutions
- Central South University (CN)
- University of Liverpool (GB)
- University of Electronic Science and Technology of China (CN)
- Sichuan Cancer Hospital (CN)
- Sichuan Academy of Traditional Chinese Medicine (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fphar.2025.1667500
- Primary Topic
- Traditional Chinese Medicine Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00